Clinical Trial

Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF

Study acronym: FMF
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 20, 2025 (before its estimated December 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate the intestinal mucosal expression of key inflammatory markers, namely Interleukin-1 (IL-1), Interleukin-18 (IL-18), and Caspase-1, in patients with Familial Mediterranean Fever (FMF). FMF is an autoinflammatory disorder characterized by recurrent episodes of fever and serosal inflammation. Recent studies suggest a possible role of intestinal immune activation in the disease pathogenesis, particularly through inflammasome-related cytokines. To better understand mucosal involvement in FMF, immunohistochemical staining for IL-1, IL-18, and Caspase-1 will be performed on intestinal biopsy samples obtained during routine endoscopic procedures. The staining intensity and distribution patterns will be evaluated and compared with age- and sex-matched healthy controls. The findings may help clarify mucosal inflammatory pathways involved in FMF and provide insight into novel therapeutic targets.
Trial Details
NCT Number NCT06981520
Lead Sponsor Hitit University
Conditions Familial Mediterranean Fever, Intestinal Disease, Genetic Disease, Fever
Enrollment 30 participants
Start Date 2025-07-10
Primary Completion 2025-12-10 (estimated)
Study Completion 2026-01-19 (estimated)
Updated on ClinicalTrials.gov 2025-05-20